KR101960102B1 - 비강내 전달을 위한 방법 및 조성물 - Google Patents

비강내 전달을 위한 방법 및 조성물 Download PDF

Info

Publication number
KR101960102B1
KR101960102B1 KR1020127030060A KR20127030060A KR101960102B1 KR 101960102 B1 KR101960102 B1 KR 101960102B1 KR 1020127030060 A KR1020127030060 A KR 1020127030060A KR 20127030060 A KR20127030060 A KR 20127030060A KR 101960102 B1 KR101960102 B1 KR 101960102B1
Authority
KR
South Korea
Prior art keywords
virus
vaccine
powder
antigen
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127030060A
Other languages
English (en)
Korean (ko)
Other versions
KR20130064741A (ko
Inventor
료이치 나가타
?지 하루타
Original Assignee
신 니뽄 바이오메디칼 라보라토리즈, 엘티디.
케이엠 바이올로직스 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 신 니뽄 바이오메디칼 라보라토리즈, 엘티디., 케이엠 바이올로직스 가부시키가이샤 filed Critical 신 니뽄 바이오메디칼 라보라토리즈, 엘티디.
Publication of KR20130064741A publication Critical patent/KR20130064741A/ko
Application granted granted Critical
Publication of KR101960102B1 publication Critical patent/KR101960102B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M3/00—Automatic or semi-automatic exchanges
    • H04M3/42—Systems providing special services or facilities to subscribers
    • H04M3/50—Centralised arrangements for answering calls; Centralised arrangements for recording messages for absent or busy subscribers ; Centralised arrangements for recording messages
    • H04M3/51—Centralised call answering arrangements requiring operator intervention, e.g. call or contact centers for telemarketing
    • H04M3/5116—Centralised call answering arrangements requiring operator intervention, e.g. call or contact centers for telemarketing for emergency applications
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/90—Services for handling of emergency or hazardous situations, e.g. earthquake and tsunami warning systems [ETWS]
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W76/00—Connection management
    • H04W76/50—Connection management for emergency connections
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W76/00—Connection management
    • H04W76/10—Connection setup
    • H04W76/15—Setup of multiple wireless link connections
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W8/00—Network data management
    • H04W8/18—Processing of user or subscriber data, e.g. subscribed services, user preferences or user profiles; Transfer of user or subscriber data
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Business, Economics & Management (AREA)
  • Signal Processing (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Emergency Management (AREA)
  • Environmental & Geological Engineering (AREA)
  • Marketing (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
KR1020127030060A 2010-04-15 2011-04-15 비강내 전달을 위한 방법 및 조성물 Active KR101960102B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32454210P 2010-04-15 2010-04-15
US61/324,542 2010-04-15
PCT/JP2011/002225 WO2011129120A1 (en) 2010-04-15 2011-04-15 Methods and compositions for intranasal delivery

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020127025573A Division KR20130083376A (ko) 2010-04-15 2011-04-15 비강내 전달을 위한 방법 및 조성물

Publications (2)

Publication Number Publication Date
KR20130064741A KR20130064741A (ko) 2013-06-18
KR101960102B1 true KR101960102B1 (ko) 2019-03-19

Family

ID=44798502

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020127025573A Ceased KR20130083376A (ko) 2010-04-15 2011-04-15 비강내 전달을 위한 방법 및 조성물
KR1020197006392A Expired - Fee Related KR102136036B1 (ko) 2010-04-15 2011-04-15 비강내 전달을 위한 방법 및 조성물
KR1020127030060A Active KR101960102B1 (ko) 2010-04-15 2011-04-15 비강내 전달을 위한 방법 및 조성물

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020127025573A Ceased KR20130083376A (ko) 2010-04-15 2011-04-15 비강내 전달을 위한 방법 및 조성물
KR1020197006392A Expired - Fee Related KR102136036B1 (ko) 2010-04-15 2011-04-15 비강내 전달을 위한 방법 및 조성물

Country Status (12)

Country Link
US (2) US9687536B2 (enExample)
EP (2) EP2558120A4 (enExample)
JP (5) JP5771626B2 (enExample)
KR (3) KR20130083376A (enExample)
CN (3) CN102933230B (enExample)
BR (1) BR112012026116A2 (enExample)
CA (2) CA2993242C (enExample)
CU (1) CU20120148A7 (enExample)
ES (1) ES2874817T3 (enExample)
RU (1) RU2012144612A (enExample)
SG (1) SG184304A1 (enExample)
WO (1) WO2011129120A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102933230B (zh) * 2010-04-15 2016-03-02 株式会社新日本科学 用于鼻内递送的方法和组合物
DK2790758T3 (da) 2011-12-16 2017-11-20 Indosys Ltd Kassette til en lægemiddeldosis og tilførselsindretning
TWI690322B (zh) * 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
WO2014186754A2 (en) * 2013-05-16 2014-11-20 Board Of Regents The University Of Texas System Dry solid aluminum adjuvant-containing vaccines and related methods thereof
CN104208029B (zh) * 2013-05-30 2017-06-06 上海医药工业研究院 一种鼻用疫苗组合物粉体制剂及其制备方法
ES2897659T3 (es) 2013-09-03 2022-03-02 Georgia Tech Res Inst Formulaciones de vacunas térmicamente estables, procesos y microagujas que incluyen las formulaciones de vacunas
US20160228433A1 (en) * 2013-09-24 2016-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal dhe for the treatment of headache
IL310015B1 (en) 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial formulation
EP3127550A1 (en) * 2015-08-07 2017-02-08 HSC Development GmbH Stabilizing composition for dry formulation of virus
US11311615B2 (en) * 2015-09-16 2022-04-26 Shin Nippon Biomedical Laboratories, Ltd. Vaccine compositions
GB201610628D0 (en) * 2016-06-17 2016-08-03 Mihranyan Albert New compositions
CA3037337A1 (en) * 2016-09-19 2018-03-22 Vaxess Technologies, Inc. Vaccine formulations with increased stability
US11022115B2 (en) 2017-06-02 2021-06-01 Purdue Research Foundation Controlled variable delivery external gear machine
WO2019021957A1 (ja) * 2017-07-25 2019-01-31 第一三共株式会社 点鼻用乾燥粉末医薬組成物
GB201713899D0 (en) 2017-08-30 2017-10-11 Indosys Ltd Multi-dose medicament delivery device
CA3083953A1 (en) 2017-12-11 2019-06-20 Board Of Regents, The University Of Texas System Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
CA3111273C (en) * 2018-09-06 2024-03-26 Bavarian Nordic A/S Storage improved poxvirus compositions
CA3122396A1 (en) 2018-12-11 2020-06-18 Satsuma Pharmaceuticals, Inc. Compositions, devices, and methods for treating or preventing headaches
KR20210129073A (ko) * 2019-02-15 2021-10-27 세럼 인스티튜트 오브 인디아 프라이비트 리미티드 생 약독화된 인플루엔자 백신 조성물 및 그의 제조 방법
EP3698773A1 (en) 2019-02-21 2020-08-26 Università degli Studi di Parma Composition and manufacturing of powders containing nanoadjuvants for mucosal vaccination
US11621604B2 (en) 2020-02-16 2023-04-04 Purdue Research Foundation Integrated electro-hydraulic machine
JP7672162B2 (ja) * 2020-03-24 2025-05-07 チョル アン，ビョン 幼い哺乳動物の粘膜関連伝染性疾病を予防または治療するための血清組成物の製造方法、前記方法によって製造された血清組成物及びその用途
CN113583970B (zh) * 2021-07-29 2023-05-12 吉林大学 一种用于预防或抗冠状病毒传播、致病的药物及其制备方法
CN119866231A (zh) 2022-09-01 2025-04-22 锡拉坎岛有限公司 干粉药物递送装置
WO2024120493A1 (en) * 2022-12-07 2024-06-13 Daocheng Zhu Formulation and use of a fusion protein
WO2024228212A1 (en) * 2023-05-01 2024-11-07 Biovet Private Limited Bio-lumpivaxin formulations and method of preparation thereof
WO2024246607A1 (en) * 2023-05-31 2024-12-05 Shin Nippon Biomedical Laboratories, Ltd. Compositions for enhanced mucosal penetration
GB202403611D0 (en) 2024-03-13 2024-04-24 Therakind Ltd Improved multi-dose medicament delivery device
CN118924744A (zh) * 2024-07-29 2024-11-12 复旦大学 小分子抑制剂ha15在抗乙型肝炎病毒中的应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5547594A (en) * 1992-11-03 1994-05-24 Secretech, Inc. Microcrystalline cellulose as an immune adjuvant
US20030092145A1 (en) 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
CN1193745C (zh) * 2001-02-27 2005-03-23 国家医药管理局上海医药工业研究院 一种鼻用鲑降钙素粉末吸入剂及制备方法
CA2467833A1 (en) 2001-11-19 2003-09-04 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
WO2003086443A1 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
MXPA06006947A (es) * 2003-12-17 2007-01-26 Wyeth Corp Metodos para producir virus de almacenamiento estable y composiciones inmunogenicas de estos.
US20060292173A1 (en) * 2004-12-13 2006-12-28 Macadam Donald H Multibacterial vaccines and uses thereof
US8784843B2 (en) 2005-09-16 2014-07-22 Merial Limited Stabilizers for freeze-dried vaccines
AU2006299310A1 (en) 2005-10-04 2007-04-12 Alk-Abello A/S Solid vaccine formulation
BRPI0616879A2 (pt) * 2005-10-04 2011-07-05 Alk Abello As formulação de vacina sólida
JP2009526526A (ja) 2006-02-13 2009-07-23 フラウンホーファー ユーエスエー， インコーポレイテッド インフルエンザ抗原、ワクチン組成物、および関連する方法
CA2646349A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
ITMI20061117A1 (it) * 2006-06-09 2007-12-10 Michele Bonanomi Una composizione farmaceutica per la somministrazione sublinguale di vaccini metodo per la sua preparazione e sui usi
JP2010502747A (ja) 2006-09-08 2010-01-28 ベクトン・ディキンソン・アンド・カンパニー ミョウバン吸着ワクチンの安定粉末製剤
AU2007303608B2 (en) * 2006-09-29 2013-05-02 Takeda Vaccines, Inc. Norovirus vaccine formulations
US8337817B2 (en) * 2006-12-26 2012-12-25 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
WO2008118691A2 (en) * 2007-03-22 2008-10-02 The Regents Of The University Of Colorado Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
WO2009006299A2 (en) 2007-06-29 2009-01-08 Dr. Reddy's Laboratories Ltd. Multi-particulate systems
EP2254594B1 (en) * 2008-03-05 2015-06-03 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
CN101601860A (zh) * 2008-06-13 2009-12-16 中国科学院过程工程研究所 疫苗
RU2011107757A (ru) 2008-08-01 2012-09-10 Гамма Ваксинс Пти Лимитед (Au) Вакцины против гриппа
EP2429495A4 (en) * 2009-05-15 2014-01-22 Shin Nippon Biomedical Lab Ltd INTRANASAL PHARMACEUTICAL COMPOSITION WITH IMPROVED PHARMACOKINETICS
GB2472327B (en) * 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
JP5491119B2 (ja) 2009-10-02 2014-05-14 日東電工株式会社 薬物含有微粒子を含む医薬組成物およびその製造方法
CN102933230B (zh) 2010-04-15 2016-03-02 株式会社新日本科学 用于鼻内递送的方法和组合物
AU2012244077B2 (en) 2010-04-15 2015-06-18 Shin Nippon Biomedical Laboratories, Ltd. Methods and compositions for intranasal delivery

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Pharmaceutical Research 2008, 25(6), 1256-1273.*

Also Published As

Publication number Publication date
CA2993242C (en) 2020-12-15
WO2011129120A1 (en) 2011-10-20
JP2019104751A (ja) 2019-06-27
KR20130083376A (ko) 2013-07-22
US9687536B2 (en) 2017-06-27
KR20190028555A (ko) 2019-03-18
EP2558120A1 (en) 2013-02-20
CA2796593C (en) 2020-12-15
CU20120148A7 (es) 2013-01-30
JP6827488B2 (ja) 2021-02-10
CN107260689A (zh) 2017-10-20
CN102933230B (zh) 2016-03-02
EP2689785A1 (en) 2014-01-29
KR20130064741A (ko) 2013-06-18
JP2013523602A (ja) 2013-06-17
EP2689785B1 (en) 2021-05-19
JP2016006119A (ja) 2016-01-14
CA2993242A1 (en) 2011-10-20
JP2017186377A (ja) 2017-10-12
CN103126996A (zh) 2013-06-05
US20130273120A1 (en) 2013-10-17
ES2874817T3 (es) 2021-11-05
RU2012144612A (ru) 2014-05-20
BR112012026116A2 (pt) 2016-06-28
SG184304A1 (en) 2012-11-29
CA2796593A1 (en) 2011-10-20
EP2558120A4 (en) 2013-08-28
KR102136036B1 (ko) 2020-07-20
JP2013126989A (ja) 2013-06-27
US10463723B2 (en) 2019-11-05
CN102933230A (zh) 2013-02-13
JP5771626B2 (ja) 2015-09-02
US20130129781A1 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
KR101960102B1 (ko) 비강내 전달을 위한 방법 및 조성물
JP7082703B2 (ja) ワクチン組成物
CN106456585B (zh) 疫苗组合物
Tian et al. Intradermal administration of influenza vaccine with trehalose and pullulan-based dissolving microneedle arrays
TWI428140B (zh) A freeze-dried preparation containing influenza vaccine and a method for producing the same
Perrie et al. Recent developments in particulate-based vaccines
US20220325250A1 (en) Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
AU2012244074B2 (en) Methods and compositions for intranasal delivery
Beukema Intradermal administration of influenza accine ith trehalose and pullulan-based dissol ing microneedle arra s
WO2025029323A1 (en) Compositions, methods, and uses for polynucleotide formulations for drying and prolonged storage
HK1139076B (en) Lyophilized preparation comprising influenza vaccine, and method for preparation thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20121116

Application number text: 1020127025573

Filing date: 20120928

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20130322

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160414

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170828

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180330

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170828

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20180330

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20171030

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20160414

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180621

Patent event code: PE09021S01D

AMND Amendment
PX0701 Decision of registration after re-examination

Patent event date: 20190103

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20180914

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20180529

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20180330

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20171030

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20160414

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
PN2301 Change of applicant

Patent event date: 20190228

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190313

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190313

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20220304

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20240304

Start annual number: 6

End annual number: 6